Galecto, Inc. (GLTO)

$ 5.61
-2.39 (-29.88%)
-
Symbol GLTO
Price $ 5.61
Beta 0.000
Volume Avg. 0.46M
Market Cap 0.14B
Shares () -
52 Week Range 4.502-17.99
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -38.26% Strong Sell
ROA -26.79% Sell
Operating Margin -
Debt / Equity 3.99% Neutral
P/E -
P/B 0.93 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

GLTO Stock Price: 60% Increase Explanation

GLTO Stock Price: 60% Increase Explanation

The stock price of Galecto Inc (NASDAQ: GLTO) increased by 60% today. This is why it happened. ...

Pulse2
Galecto Reports First Quarter Financial Results and Provides a Corporate Update

Galecto Reports First Quarter Financial Results and Provides a Corporate Update

BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the period e... ...

GlobeNewsWire
Galecto (GLTO) Enters Oversold Territory

Galecto (GLTO) Enters Oversold Territory

Galecto (GLTO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock ...

Zacks Investment Research
Galecto Reports Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Update

Galecto Reports Financial Results for the Year Ended December 31, 2020 and Provides a Corporate Upda...

BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the year e... ...

GlobeNewsWire
UPDATE: Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosis and Potential for GB0139

UPDATE: Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic ...

Tuesday, March 30, 2021 @ 2pm Eastern Time Tuesday, March 30, 2021 @ 2pm Eastern Time ...

GlobeNewsWire
Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonary Fibrosis and Potential for GB0139

Galecto Hosting Expert Perspective Panel on the Evolving Treatment Landscape for Idiopathic Pulmonar...

Tuesday, March 30, 2021 @ 2pm Eastern Time. Tuesday, March 30, 2021 @ 2pm Eastern Time. ...

GlobeNewsWire
Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends Study to Continue with Modifications

Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Stud...

Galecto expects to continue dosing patients in the 3 mg arm, whereas the 10 mg arm and combinations with nintedanib or pirfenidone will be discontinued at the recommendation of the DSMB Galecto expects to continue dosing patients in the 3 mg arm, whe... ...

GlobeNewsWire
Galecto to Present at Upcoming Investor Conferences

Galecto to Present at Upcoming Investor Conferences

BOSTON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced Hans Schambye, the Company's Chief Executive Officer, will partici... ...

GlobeNewsWire
Galecto Appoints Anne Prener to its Board of Directors

Galecto Appoints Anne Prener to its Board of Directors

BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc., (NASDAQ: GLTO) a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of Dr. Anne Prener to its Board of D... ...

GlobeNewsWire
Galecto to Take Part in Two Panel Discussions at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

Galecto to Take Part in Two Panel Discussions at the LifeSci Partners 10th Annual Healthcare Corpora...

BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, Chief Executive Officer, will pa... ...

GlobeNewsWire

About


Dr. Hans T. Schambye
Healthcare
Biotechnology
NMS

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of fibrosis related to non-alcoholic steatohepatitis, as well as development of other related indications, including cancer. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.